Strata Critical Medical, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Q3 2026 revenue rose 50.3% YoY to $74.1M, driven by clinical acquisitions (Keystone, OVPA, LPS, HLT-NRP), though logistics declined 3.5% to $44.9M. Net loss from continuing operations was $(7.6)M (vs. $(9.7)M prior year); Adjusted EBITDA $9.6M (13.0% margin, up 450bps). Company authorized $20M share repurchase and reported record $8.6M free cash flow in Q3. Cash position: $41.6M.
Why this rating
Strong revenue growth and margin expansion offset by continued GAAP losses. M&A-driven growth and buyback signal confidence; 50% topline growth material at $264M market cap but masks slowing organic trajectory (8.5% pro forma).
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.